Änderungen

*WO2018185347A1  PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INTERNAL INFLAMMATIONS<br>The invention relates to a pharmaceutical composition based on an aqueous solution of chlorine dioxide adapted as a solution for rectal intestinal lavage, as a solution for ureteral and bladder lavage or as an isotonic injection or infusion solution for use in the systemic treatment of acute or chronic internal inflammations and clinically relevant symptoms or states of the human or animal organism brought about thereby. The composition contains 5 to 1000 mg/l (ppm) of dissolved chlorine dioxide (ClO2) and is in a ready-to-use state substantially free from chlorate ions, hydrochloric acid and gaseous chlorine or contains these components in a concentration of not more than 1 mg/L (1 ppm) in each case.

*WO2018185347A1  PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INTERNAL INFLAMMATIONS<br>The invention relates to a pharmaceutical composition based on an aqueous solution of chlorine dioxide adapted as a solution for rectal intestinal lavage, as a solution for ureteral and bladder lavage or as an isotonic injection or infusion solution for use in the systemic treatment of acute or chronic internal inflammations and clinically relevant symptoms or states of the human or animal organism brought about thereby. The composition contains 5 to 1000 mg/l (ppm) of dissolved chlorine dioxide (ClO2) and is in a ready-to-use state substantially free from chlorate ions, hydrochloric acid and gaseous chlorine or contains these components in a concentration of not more than 1 mg/L (1 ppm) in each case.

*WO2018185348A1  PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE INTOXICATION<br>The invention relates to a pharmaceutical composition based on a highly pure aqueous solution of chlorine dioxide for use in the local or systemic treatment of acute intoxication caused by toxic substances from plants, mushrooms, aquatic animals, amphibians, reptiles, spiders, or insects and the clinically relevant symptoms or conditions caused thereby of human or animal organisms. The composition contains 5 to 3000 mg/l (ppm) of dissolved chlorine dioxide (CI02) and is substantially free of chlorate ions, hydrochloric acid

*WO2018185348A1  PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE INTOXICATION<br>The invention relates to a pharmaceutical composition based on a highly pure aqueous solution of chlorine dioxide for use in the local or systemic treatment of acute intoxication caused by toxic substances from plants, mushrooms, aquatic animals, amphibians, reptiles, spiders, or insects and the clinically relevant symptoms or conditions caused thereby of human or animal organisms. The composition contains 5 to 3000 mg/l (ppm) of dissolved chlorine dioxide (CI02) and is substantially free of chlorate ions, hydrochloric acid

==Siehe auch==

==Siehe auch==

*[[Behandlungsexperimente der COVID-19 Erkrankung mit Chlordioxid]]

*[[Behandlungsexperimente der COVID-19 Erkrankung mit Chlordioxid]]